Research
Cellular
Semaglutide (SEM) and tirzepatide (TIR) use was associated with greater annualized total hip (TH) bone loss in patients without diabetes mellitus (DM) compared to controls.
Practitioners should monitor bone health in patients using GLP-1 RAs, especially those without DM.
StrongSupportsmedium confidence
Among patients without DM, greater TH bone loss was noted in GLP-1 RA group compared to controls (-1% vs -0.6%, p=0.04).
Why this rating
Based on a retrospective study design with matched controls.
Source
Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
Yi Liu et al. · The Journal of Clinical Endocrinology & Metabolism · 2026
DOI 10.1210/clinem/dgag052
cohort · n=510Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →